![Full Text of PDF](img/ico_pdf_full.gif)
![required ID / password](img/ico_sec.gif)
Article in Japanese
A case of Hamman’s syndrome that presented with chest pain that developed after administration of SGLT2 inhibitors
Yoshinobu Naganoa Manato Taguchia Ryusei Nakagawab Mao Sasamotoa Takeshi Kawakamia Kyoko Kondoa
aDepartment of Respiratory Medicine, Kobari General Hospital
bDepartment of Respiratory Medicine, Ibaraki Seinan Medical Center Hospital
The patient was a 16-year-old man who had visited another hospital with a chief complaint of vomiting. He was diagnosed with type 2 diabetes and prescribed tofogliflozin.
Six days later, he became aware of chest pain and difficulty breathing and called for an ambulance. As a result of close examination, pneumomediastinum and diabetic ketoacidosis were detected, so he was diagnosed with Hamman’s syndrome and hospitalized. He required tracheal intubation and dialysis management but was discharged after improvement following an infusion and insulin treatment.
Only one case of Hamman’s syndrome involving SGLT2 inhibitors has been reported; we therefore present this case because we consider it to be valuable.
Pneumomediastinum Diabetic ketoacidosis (DKA) Hamman’s syndrome Tofogliflozin
Received 27 Apr 2023 / Accepted 10 Oct 2023
AJRS, 13(1): 39-43, 2024